An ac­quis­i­tive Cel­gene looks ready to pop a new mul­ti­ple myelo­ma deal

Is Cel­gene $CELG about to un­veil a new deal BC­MA-tar­get­ing deal? A sharp-eyed Bri­an Abra­hams at Jef­feries spot­ted a no­tice post­ed at the FTC cit­ing Cel­gene as the “ac­quir­ing par­ty” for En­gMab, a Swiss biotech work­ing on bis­pe­cif­ic an­ti­bod­ies that are co­va­lent to BC­MA — a hot tar­get for Cel­gene — and CD3.

A Cel­gene spokesper­son says there’s no deal — yet.

“A deal has not com­plet­ed,” the spokesper­son said in an email to me. “We can­not com­ment any fur­ther at this time.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.